Maud Jonnaert

414 total citations
8 papers, 321 citations indexed

About

Maud Jonnaert is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maud Jonnaert has authored 8 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maud Jonnaert's work include CAR-T cell therapy research (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Maud Jonnaert is often cited by papers focused on CAR-T cell therapy research (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Maud Jonnaert collaborates with scholars based in United States, Canada and United Kingdom. Maud Jonnaert's co-authors include Hugh J. Clarke, Cassandre Labelle‐Dumais, Daniel Dufort, Kazuki Kuroda, Othman A. Mohamed, Wendy Osborne, Takashi Seto, Lecia V. Sequist, Susan E. Moody and Enriqueta Felip and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Maud Jonnaert

8 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maud Jonnaert United States 6 146 122 99 88 61 8 321
Daniel Y. Paik United States 9 68 0.5× 140 1.1× 107 1.1× 143 1.6× 55 0.9× 11 350
Kristen Bunch United States 8 64 0.4× 140 1.1× 101 1.0× 94 1.1× 15 0.2× 18 311
Nozomi Yachida Japan 9 117 0.8× 106 0.9× 66 0.7× 226 2.6× 16 0.3× 19 357
Marcin Jędryka Poland 11 81 0.6× 59 0.5× 71 0.7× 167 1.9× 23 0.4× 34 303
Jake J. Reske United States 9 87 0.6× 197 1.6× 48 0.5× 77 0.9× 8 0.1× 15 308
Petra Bilinski United States 5 174 1.2× 174 1.4× 64 0.6× 92 1.0× 34 0.6× 7 356
Hao Ran United States 3 41 0.3× 93 0.8× 105 1.1× 112 1.3× 36 0.6× 4 236
M. Nishida Japan 5 84 0.6× 133 1.1× 46 0.5× 311 3.5× 20 0.3× 9 453
Zongwen Liang China 9 116 0.8× 142 1.2× 29 0.3× 143 1.6× 12 0.2× 15 304
Moito Iijima Japan 8 42 0.3× 152 1.2× 78 0.8× 92 1.0× 10 0.2× 18 315

Countries citing papers authored by Maud Jonnaert

Since Specialization
Citations

This map shows the geographic impact of Maud Jonnaert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maud Jonnaert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maud Jonnaert more than expected).

Fields of papers citing papers by Maud Jonnaert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maud Jonnaert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maud Jonnaert. The network helps show where Maud Jonnaert may publish in the future.

Co-authorship network of co-authors of Maud Jonnaert

This figure shows the co-authorship network connecting the top 25 collaborators of Maud Jonnaert. A scholar is included among the top collaborators of Maud Jonnaert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maud Jonnaert. Maud Jonnaert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Tan, Daniel S.W., Natasha B. Leighl, Gregory J. Riely, et al.. (2020). Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. The Lancet Respiratory Medicine. 8(6). 561–572. 43 indexed citations
2.
Tholouli, Eleni, Wendy Osborne, Carlos Bachier, et al.. (2020). 890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. Annals of Oncology. 31. S651–S651. 4 indexed citations
3.
Osborne, Wendy, Maria A. V. Marzolini, Eleni Tholouli, et al.. (2020). Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.. Journal of Clinical Oncology. 38(15_suppl). 8001–8001. 36 indexed citations
4.
5.
Tan, Daniel Shao-Weng, Dong‐Wan Kim, Natasha B. Leighl, et al.. (2017). Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). 11506–11506. 11 indexed citations
6.
7.
Labialle, Stéphane, Sylvie Croteau, Sanny Moussette, et al.. (2008). Novel imprinted transcripts from theDlk1-Gtl2intergenic region,Mico1andMico1os, show circadian oscillations. Epigenetics. 3(6). 322–329. 16 indexed citations
8.
Mohamed, Othman A., Maud Jonnaert, Cassandre Labelle‐Dumais, et al.. (2005). Uterine Wnt/β-catenin signaling is required for implantation. Proceedings of the National Academy of Sciences. 102(24). 8579–8584. 190 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Y. Paik Breakdown of academic impact, for papers by Kristen Bunch Breakdown of academic impact, for papers by Nozomi Yachida Breakdown of academic impact, for papers by Marcin Jędryka Breakdown of academic impact, for papers by Jake J. Reske Breakdown of academic impact, for papers by Petra Bilinski Breakdown of academic impact, for papers by Hao Ran Breakdown of academic impact, for papers by M. Nishida Breakdown of academic impact, for papers by Zongwen Liang Breakdown of academic impact, for papers by Moito Iijima
Rankless by CCL
2026